has selected XIFAXAN ® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of ...

XIFAXAN® (rifaximin) 550 mg tablets, for the upcoming round of drug price negotiations. According to InvestingPro analysis, the company currently trades below its Fair Value, suggesting potential ...

Amneal Pharmaceuticals (AMRX) announced that the FDA has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

(rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price ...

Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in ...

All subjects underwent lactulose/methane breath test (LBT) to assess SIBO before and one month after the treatment with Rifaximin 600 mg daily. All IBS pts filled out a Visual Analogic Scale (VAS ...